November 2, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Jason Drory
Re: Aadi Bioscience, Inc.
Registration Statement on Form S-3
File No. 333-268021
Acceleration Request
Requested Date: November 4, 2022
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aadi Bioscience, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-268021) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at dkoeppen@wsgr.com.
[Signature page follows]
Securities and Exchange Commission
November 2, 2022
Page 2
| Sincerely, |
| AADI BIOSCIENCE, INC. |
| /s/ Neil Desai |
| Neil Desai |
| President and Chief Executive Officer |
| cc: | Dan Koeppen, Wilson Sonsini Goodrich & Rosati, P.C. |
Robert L. Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.
David G. Sharon, Wilson Sonsini Goodrich & Rosati, P.C.